Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 157

Results For "IMI"

4127 News Found

Biocon receives approval from SAHPRA for Tacrolimus Capsule
News | April 22, 2024

Biocon receives approval from SAHPRA for Tacrolimus Capsule

Tacrolimus is an immunosuppressant used in the treatment of organ transplant patients


Zydus launches Mirabegron ER Tablets in the US
Drug Approval | April 22, 2024

Zydus launches Mirabegron ER Tablets in the US

Zydus is among the first suppliers to launch the generic version of Mirabegron Extended-Release Tablets, USP 25 mg in the US market


Akums launches Bharosa campaign
News | April 22, 2024

Akums launches Bharosa campaign

The campaign marks an important milestone in its journey within the pharmaceutical manufacturing industry


Jubilant Pharmova to close manufacturing operations of Solid dosage formulation facility of Jubilant Cadista USA
News | April 19, 2024

Jubilant Pharmova to close manufacturing operations of Solid dosage formulation facility of Jubilant Cadista USA

The US Generics market has been witnessing significant pricing pressure leading to significant losses at Jubilant Cadista since FY2022 onwards.


Shilpa Medicare launches Pemetrexed injection
News | April 19, 2024

Shilpa Medicare launches Pemetrexed injection

Pemetrexed Injection is used as a drug, in the treatment of non-small cell lung cancer in combination with other chemotherapy agents


Fresenius Kabi USA flies complaint against NATCO Pharma
News | April 19, 2024

Fresenius Kabi USA flies complaint against NATCO Pharma

Natco Pharma intends to defend the matter accordingly


Dr. Reddy’s launches integrated care plan to manage irritable bowel syndrome
Digitisation | April 19, 2024

Dr. Reddy’s launches integrated care plan to manage irritable bowel syndrome

Around 7% of the Indian population suffers from IBS


Biocon inks agreement for Ozempic commercialization in Brazil with Biomm
News | April 19, 2024

Biocon inks agreement for Ozempic commercialization in Brazil with Biomm

Biocon will undertake the development, manufacturing and supply of the drug product, and Biomm will be responsible for obtaining regulatory approval and commercialization in the Brazilian market


Jubilant Pharmova’s Roorkee unit gets VAI status
Drug Approval | April 18, 2024

Jubilant Pharmova’s Roorkee unit gets VAI status

FDA has concluded that this inspection is 'closed'